Medtronic to split off its fast-growing diabetes business to unlock its value

Medtronic (MDT) announced it will spin off its diabetes business, its fastest-growing segment with 10.4% revenue growth to $728 million in the recent quarter, into a new publicly traded company via an IPO within 18 months. The separation aims to unlock value by creating a shareholder base more aligned with the diabetes business's financial profile and is expected to be accretive to Medtronic's gross margin, operating margin, and EPS; concurrently, Medtronic reported Q4 results with net income up 61.6% to $1.06 billion and raised its quarterly dividend by a penny to $0.71 per share.

Analysis

Medtronic PLC (MDT) has announced a strategic decision to separate its rapidly expanding diabetes business into a new, independent publicly traded company within the next 18 months, with an initial public offering being the preferred route. This move is designed to unlock shareholder value by establishing a distinct investor base aligned with the diabetes unit's financial profile and is anticipated to be accretive to Medtronic's gross margin, operating margin, and earnings per share. The diabetes segment, though Medtronic's smallest, was its fastest-growing, with fiscal fourth-quarter revenue jumping 10.4% year-over-year to $728 million, marking its sixth consecutive quarter of double-digit percentage growth and exceeding the FactSet analyst consensus of $709.7 million. The new entity will focus on a business-to-consumer model offering a "complete intensive insulin management ecosystem," contrasting with Medtronic's existing business-to-business approach, amidst a backdrop of increasing demand for diabetes and weight-loss treatments. Concurrently, Medtronic reported robust fiscal fourth-quarter results: net income surged 61.6% to $1.06 billion, and adjusted earnings per share rose to $1.62 from $1.46, surpassing the analyst estimate of $1.58. Overall net sales increased 3.9% to $8.93 billion, also beating forecasts, with cardiovascular revenue up 6.6%, neuroscience up 2.9%, and medical surgical revenue up 0.6%. Reflecting confidence, Medtronic raised its quarterly dividend by a penny to $0.71 per share, implying an attractive dividend yield of 3.27%. The company's stock has responded positively, gaining 8.7% in 2025 and outperforming both the Health Care Select Sector SPDR ETF and the S&P 500 index.

Key Decisions for Investors

• Investors should evaluate Medtronic's planned spin-off of its high-growth diabetes division as a positive catalyst, given its potential to enhance Medtronic's profitability metrics and unlock distinct value through a more focused corporate structure.
• The forthcoming IPO of the new diabetes company warrants close attention as it will present a pure-play investment opportunity in a business-to-consumer focused entity operating within the expanding diabetes care market, particularly in intensive insulin management.
• Considering Medtronic's strong Q4 earnings which surpassed analyst expectations, coupled with a raised dividend yielding 3.27%, investors may find the remaining Medtronic entity an attractive proposition, holding potential for continued growth in its core cardiovascular, neuroscience, and medical surgical businesses post-separation.